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Abstract: TiO2 nanoparticles (NPs) are one of the most produced NPs worldwide and are used in 
many consumer products. Their impact on human health, especially through inhalation, has been 
studied for more than two decades. TiO2 is known for its strong affinity towards phosphates, and 
consequently interaction with cellular phosphates may be one of the mechanisms driving its 
toxicity. In the present study, we used a phosphoproteomics approach to document the interaction 
of TiO2-NP with phosphoproteins from A549 human pulmonary alveolar epithelial cells. Cells were 
exposed to 21 nm anatase/rutile TiO2-NPs, then their phosphopeptides were extracted and analyzed 
using shotgun proteomics. By comparing the phosphoprotein content, phosphorylation status and 
phosphorylation sites of exposed cells with that of control cells, our results show that by affecting 
the phosphoproteome, TiO2-NPs affect cellular processes such as apoptosis, linked with cell cycle 
and the DNA damage response, TP53 being central to these pathways. Other pathways including 
inflammation and molecular transport are also affected. These molecular mechanisms of TiO2-NP 
toxicity have been reported previously, our study shows for the first time that they may derive from 
phosphoproteome modulation, which could be one of their upstream regulators. 
Keywords: omics; lung; inhalation; nanoparticle; TiO2; proteomics; phosphoproteomics 
 
1. Introduction 
Titanium dioxide (TiO2) is widely used in daily products as a white pigment, for example, as a 
food additive and in paints [1]. It is also used in cosmetics as a UV filter [1]. The annual production 
of nanosized TiO2 ranges between 3800 and 7800 tons in the US. With such a large production, TiO2-
NPs could be present in 9% of nanomaterial-containing products [2]. 
The impact of TiO2-NPs on the lung has been the subject of intense research since inhalation is 
considered as being the first and most problematic route of occupational exposure. In vivo, exposure 
to TiO2-NP either via intratracheal instillation or inhalation causes pulmonary inflammation, fibrosis 
and emphysema-like response [1,3–5]. TiO2 is classified as possibly carcinogenic (2B group) via 
inhalation by the International Agency for Research on Cancer (IARC) [6]. In vitro, TiO2-NPs are 
endocytosed in a plethora of cell models [7]. When internalized in cells, TiO2 accumulates in 
endosomes and is transferred to lysosomes. Although there is no evidence of its accumulation in 
mitochondria, TiO2 induces oxidative stress in exposed cells by increasing the intracellular level of 
reactive oxygen species (ROS) and impairing the antioxidant cellular response [3,8]. This effect has 
Nanomaterials 2020, 10, 185 2 of 23 
 
been shown to be associated with the inhibition of the nuclear factor (erythroid-derived 2)-like 2 
(NRF2) in BEAS-2B lung cells [9] and in mice kidneys [10]. TiO2 also causes oxidative damage to DNA 
without accumulating inside cell nucleus, except if the cell has undergone mitosis, one of the stages 
of which is the rupture of the nuclear envelope [11]. This genotoxicity is concomitant to impairment 
of the mitotic spindle assembly and function [12], decreased DNA repair activities [13,14] and cell 
cycle progression [15–20], suggesting that TiO2-NPs exert indirect primary genotoxicity [11]. Finally, 
TiO2-NPs have been shown to affect the autophagic process [21,22], and this property has been 
proposed as a possible therapeutic approach to treat cancer [23]. The main driver of these cellular 
effects is currently unknown and whether multiple factors are involved remains to be established. 
Phosphate is essential for cell survival. Protein phosphorylation/dephosphorylation reactions, 
carried out by kinases and phosphatases, regulate the activity of almost all cellular processes [24,25] 
TiO2 shows high affinity for phosphate groups, due to its ion exchange abilities and ligand exchange 
behavior towards Lewis bases (for review, see [26]) and for this reason it has long been used to purify 
phosphoproteins [27,28]. Since TiO2-NPs heavily accumulate in cytoplasmic vesicles, they may 
adsorb phosphoproteins on their surface, sequester them in these vesicles, and consequently interfere 
with their proper function. Moreover, kinases and phosphatases are phosphoproteins; their 
sequestration on the surface of TiO2-NPs may hinder their role in maintaining the pool of cellular 
phosphoproteins. Therefore, we hypothesized that the impact of TiO2 on protein phosphorylation 
status could be one upstream mechanism driving its toxicity. This hypothesis is supported by some 
results showing impact of TiO2-NPs on cellular phosphoproteins. For instance, exposure of BEAS-2B 
cells to TiO2-NPs increases the phosphorylation level of several central kinases, including P38, c-Jun 
NH2- terminal protein kinases (JNKs), mitogen-activated protein kinase/extracellular signal-
regulated kinase (ERK1/2), mitogen- and stress-activated protein (MSK1), glycogen synthase kinase 
(GSK), AMP-activated protein kinase (AMPK), signal transducer and activator of transcription 
(STAT) and the tyrosine protein-kinase FYN [29]. 
Consequently, the aim of this study was to characterize the impact of TiO2-NPs on protein 
phosphorylation profile in lung cells. Rather than using a case-by-case method, we used a large-scale 
approach, i.e., phosphoproteomics. This approach provides an exhaustive view of cellular 
phosphoproteome alteration in cells exposed to TiO2-NPs as compared to unexposed cells. We used 
a label-free phosphoproteomics approach consisting in enriching cellular phosphopeptides, then 
identifying and quantifying them by shotgun proteomics. This approach was applied to A549 human 
lung epithelial alveolar cells, exposed for 24 h to 100 µg/mL of 21 nm anatase/rutile TiO2-NP, i.e., 17 
µg/cm2 equivalent to 0.11 ng/cell. This concentration corresponds to the alveolar deposition of TiO2-
NP after inhalation exposure to 1 mg/m3 for a whole working lifetime [30]. Therefore, it can be 
considered as a worst-case exposure scenario. This exposure condition leads to moderate cell 
mortality, as inferred from our previous studies [14,31]. 
2. Materials and Methods 
2.1. Chemicals and Nanoparticles 
Unless otherwise indicated, chemicals were purchased from Sigma-Aldrich (Saint-Quentin 
Fallavier, France) and were >99% pure. NM105 TiO2-NPs were supplied by the Joint Research Center 
of the European Commission (JRC, Ispra, Italy). These NPs exhibit a spherical, ellipsoidal, and 
cuboidal structure, are 86% anatase and 14% rutile. Their diameter is 21 nm and their specific surface 
area 46 m2/g [32]. NPs were dispersed in ultrapure sterile water, by sonicating them in water for 30 
min at 4 °C, using a high energy sonicator in pulsed mode (1 s on/1 s off), using an Autotune 750 W 
sonicator from Fisher Bioblock Scientific (Rungis, France) operated at 30% of amplitude, as previously 
described [14,31]. According to the calorimetric procedure, this corresponds to 19.82 W [33,34]. 
Suspensions were diluted in serum-free cell culture medium immediately before cell exposure. Their 
hydrodynamic diameter was 70 ± 20 nm with a 0.18 ± 0.04 polydispersity index (PDI) in water; it 
shifted to 720 ± 20 nm (PDI: 0.50 ± 0.02) after dilution in the exposure medium (mean ± standard 
deviation, n = 3, not shown). 
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2.2. Cell Culture and Exposure Conditions 
This study was performed on A549 human epithelial alveolar cells (A549, ATCC CCL-185), 
grown in DMEM as previously [14]. The use of this cell line in toxicity studies has been criticized 
because it exhibits a constitutively active NRF2 [35]. However, we chose to use it in the present study 
because to our knowledge it is the only available cell line of human alveolar origin and NPs have 
been shown to deposit in this region of the lung due to their small size [36]. They were exposed, 3 
days after seeding, to 100 µg/mL of TiO2-NPs diluted in serum-free cell culture medium, with three 
biological replicates per condition (n = 3), then rinsed three times with PBS and harvested using 
trypsin. This concentration corresponds to 17 µg TiO2/cm2, i.e., 0.11 ng TiO2/cell. At this concentration, 
these NPs cause approximately 25% of cell viability loss (as shown in [31], where these NPs are 
referred to as “TiO2-Degussa” and in [13]), but significantly increases intracellular reactive oxygen 
species level, causes DNA damage and significantly increases the DNA repair activities in A549 cells 
(as shown in [14], in this article these NPs are referred to as “A25”, and in [13]). Cell exposure was 
performed in the dark in order to avoid any photocatalytic effect of TiO2-NPs. 
2.3. Phosphoproteome Sample Preparation and Trypsin Proteolysis 
The phosphoproteomics experiment was performed with 1.2 × 107 cells per replicate, which were 
sampled using trypsin and flash frozen in liquid nitrogen. Samples were stored at −80 °C until 
analysis. The samples were melted on ice in a lysis buffer consisting in 50 mM Tris/HCl, pH 8.2, 8 M 
urea, 75 mM NaCl and 2X phosphatase inhibitor cocktail (Thermo Scientific, Illkirch, France, 88667). 
They were then sonicated three times using a Hielsher (Teltow, Germany) UP50H probe sonicator, 
operated in pulse mode (20 s at 0.4 s on/0.4 s off) at 40% amplitude, with a pause of 1 min between 
each cycle of sonication. After centrifugating these lysates at 16,000 × rcf for 10 min, 4 °C, the 
supernatants were stored at −80 °C. After thawing, protein concentration in the samples was 
measured using Bradford reagent (Interchim, Montluçon, France, CooAssay Standard Protein Assay 
kit), using the protocol of the supplier. The reduced cysteine residues were alkylated by reaction with 
iodoacetamide (5 mM), for 15 min at room temperature. After dilution with 100 mM Tris/HCl, pH 
8.5, to reach an urea concentration of 1 M, the samples were digested overnight at 37 °C using 1 
mg/mL trypsin prepared in a 0.01% aqueous solution of trifluoroacetic acid, so that the final 
concentration of protein was 2% per sample. After centrifugating for 1 min at 1000 rcf, at room 
temperature, the supernatants were stored at −80 °C. SDS-PAGE followed by Coomassie blue staining 
was used to evaluate the extent of proteolysis. 
2.4. Phosphopeptide Enrichment by Chromatography 
Digested samples were desalted using Harvard Apparatus (Holliston, MA, USA) Macro Spin 
C18 Columns, using the protocol of the supplier, consisting in (i) activation of the resin in 500 µL of 
80% acetonitrile, 20% water, repeated three times, (ii) equilibration of the columns by rinsing with 
500 µL 0.5% trifluoroacetic acid, three times. 250 µg of digested peptides was loaded onto columns, 
which were then centrifuged at room temperature for 30 s at 2000 rcf. The filtrates were then collected 
and loaded again onto the columns. At the end of this procedure, the resins were rinsed three times 
with 0.5% trifluoroacetic acid and peptides were eluted in 100 µL of 1:1 acetonitrile/water, 0.1% TFA. 
These desalted peptides were freeze-dried and stored at −80 °C. 
As described in Figure 1, the samples were then subjected to two consecutive chromatographies. 
The first one was a strong cation exchange chromatography (SCX), which was processed as 
previously described [37], using a polysulfoethyl ATM column (PolyLC, Columbia, MD, USA, 3.2-
mm inner diameter, 200 mm length, 5-µm particle size, 200 Å pore size) operated at a flow rate of 400 
µL/min on a 1100 Series reverse-phase high performance liquid chromatography (HPLC) system 
equipped with a G1315B diode array detector, a G1322A degasser and a G1311A quaternary pump, 
as well as a G1329A autosampler, and sample cooler unit from Agilent (Les Ulis, France) [38]. Samples 
(1 mg of peptide) were diluted in 65 µL of buffer A (7 mM KH2PO4, pH 2.65 and 30% acetonitrile 
(vol./vol.)) and 60 µL was injected in the column. The stepwise elution was performed with three 
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buffers: buffer A, buffer B (7 mM KH2PO4, 350 mM KCl, pH 2.65, 30% acetonitrile (vol./vol.)), buffer 
C (50 mM K2HPO4, 500 mM NaCl, pH 7.5) and ultrapure water. Buffer A was applied to the column 
from time 0 to min 34. Then we applied 75% buffer A and 25% buffer B for one min, then buffer B 
from min 36 to 41, then ultrapure water from min 42 to 48. Buffer C was then applied from min 49 to 
60, followed by ultrapure water from min 61 to 67. Finally, Buffer A was applied from min 68 to 120. 
Phosphopeptide samples were collected as two separate fractions of 4 min-elution, between min 8 
and min 16, as described previously [37]. These two separate fractions were freeze-dried in order to 
reach a final volume of 150 µL, to which was added 350 µL of 0.1% TFA. The samples were desalted 
as previously. The second chromatography was used to enrich phosphopeptides, and consisted in 
immobilized metal affinity chromatography (IMAC). The resin was the PhosSelect Iron Affinity Gel 
resin (Sigma-Aldrich, Saint-Quentin Fallavier, France, P9740), to which samples were bound as 
previously described [37]. Peptides were then desalted as described above, except that samples were 
rinsed with 200 µL instead of 500 µL. To do so, the resin was loaded on activated and equilibrated 
Harvard Apparatus (Holliston, MA, USA) Micro Spin C18 columns. Therefore, we obtained a two-
layered resin, which was rinsed twice with 100 µL of 40% acetonitrile, 60% 25 mM formic acid (IMAC 
binding buffer) and once with 200 µL of C18 wash solution. Phosphopeptides were eluted from the 
PhosSelect resin and retained on the underlying C18 resin by adding three times 100 µL of 500 mM 
K2HPO4, pH 7 (IMAC elution buffer). The resin was rinsed four times with 200 µL of C18 wash 
solution and phosphopeptides were eluted twice using 50 µL of C18 elution solution. These two 
eluted fractions were pooled. Samples were then freeze-dried and stored at −80 °C. 
 
Figure 1. Experimental strategy. The phosphoproteomic analysis was performed on control (Ctrl) and 
TiO2-NP-exposed cells (TiO2), with three biological replicates per condition (A, B and C). SCX: strong 
cation exchange (chromatography); IMAC: immobilized metal affinity chromatography; NanoLC-
MS/MS: nano liquid chromatography coupled to tandem mass spectrometry. 
2.5. Tandem Mass Spectrometry 
Phosphopeptides (10 µL) were loaded on the LTQ Orbitrap XL hybrid nano-liquid 
chromatography coupled to tandem mass spectrometry (nanoLC-MS/MS) system (ThermoFisher 
Scientific, Les Ulis, France) coupled to Ultimate 3000 LC system (Dionex-ThermoFisher Scientific, Les 
Ulis, France), after dissolution in 30 µL of 0.1% TFA. The analysis conditions were as described by 
Dedieu et al. [39]. Full-scan mass spectra were measured from m/z 300 to 1800. The mass spectrometer 
was operated in data-dependent mode using a TOP3 strategy consisting in a scan cycle initiated with 
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a full scan of high mass accuracy in the Orbitrap (30,000 resolution; internal calibration), followed in 
parallel by MS/MS normal mode scans in the linear ion trap on the three most abundant precursor 
ions. The parameters were set as follows: minimum signal required: 15,000; possible charge states: 2+ 
and 3+; dynamic exclusion of previously-selected ions with 60 sec exclusion duration. The previously 
described Multi Stage Activation mode (pseudo-MS3) [40] was activated with a neutral lost mass list 
including 32.6590 (phosphate, triple positive charges) and 48.9890 (phosphate, double positive 
charges). The lock mass option on the LTQ Orbitrap XL mass spectrometer was enabled in MS mode 
and the polydimethylcyclosiloxane ions generated in the electrospray process from ambient air 
(protonated [(CH3)2SiO)]6 with m/z at 445.12002) were used for internal recalibration in real time. 
2.6. MS/MS Spectra Interpretation, Statistics, and Data Mining 
Peak lists were generated with the MASCOT DAEMON software (Matrix Science, London, UK, 
version 2.3.2) using the extract_msn.exe data import filter from the Xcalibur FT package (version 
2.0.7) (ThermoFisher Scientific, Les Ulis, France). The filtering options were, as previously [41]: 
minimum mass: 400, maximum mass: 5000, grouping tolerance: 0, intermediate scans: 0, minimum 
peaks: 10, extract MSn: 2 and threshold: 1000. Peptides were assigned from MS/MS spectra according 
to the SwissProt database with the MASCOT 2.3.02 software (Matrix Science, London, UK), by 
searching the database with the following parameters: Mammalia taxonomy (65,476 sequences), 
SwissProt_2012_02, maximum number of miss-cleavages: 2; mass tolerances: 5 ppm (parent ion) and 
0.5 Da (MS/MS); carbamidomethylated Cys: fixed modification; and oxidized Met and 
phosphorylated Ser, Thr and Tyr residues: variable modification. MASCOT results were analyzed 
using IRMa 1.30.4 [32] software, which filters out peptides with a p-value of less than 0.01 and a rank 
set to 1. Fold-changes represent the ratio of values obtained in samples exposed to TiO2 and samples 
from control cells, based on spectral counts after standard normalisation. PatternLab software was 
used for normalization and statistical significance assessment [42]. The cut-off values to consider 
results as statistically significant was p < 0.05 and fold-change > 1.5. Gene ontology and pathway 
analyses were performed using Database for Annotation, Visualization and Integrated Discovery 
(David) [43,44] and Ingenuity® Pathway Analysis (IPA®—23814503, QIAGEN, Courtaboeuf, France). 
Enriched pathways were considered statistically significant when p < 0.05. 
2.7. Cell Cycle Analysis 
Cells were exposed to 100 µg/mL of TiO2-NPs, then rinsed three times with PBS containing 2 
mM of EDTA. Then they were fixed for 30 min in 70% ice-cold ethanol and diluted in PBS-EDTA (2 
mM). This fixative solution was removed and cells were suspended in 25 µg/mL propidium iodide 
prepared in PBS-EDTA (2 mM) to which was added 25 µg/mL RNase A. Samples were analyzed by 
flow cytometry using a FACS Calibur (Becton Dickinson, Rungis, France). This experiment was 
repeated three times independently, with four replicates per experiment. 
2.8. Electron Microscopy 
Cells exposed to 100 µg/mL TiO2-NPs for 24 h were washed three times with phosphate saline 
buffer, fixed with 2.5% glutaraldehyde and post-fixed with OsO4. They were then dehydrated by 
immersion in solutions of ethanol with increasing concentration and embedded in Epon. Ultrathin 
sections were prepared by ultramicrotomy and counterstained with uranyl acetate and lead citrate. 
These samples were observed using a CM12 Philips electron microscope, operating at 80 kV. 
3. Results and Discussion 
Cell exposure conditions were chosen based on results that we previously obtained, showing 
mild cytotoxicity of TiO2-NPs to A549 cells, i.e., less than 25% of cell mortality in exposed cells 
according to the MTT assay. Moreover, we previously showed that this exposure condition leads to 
a significant elevation of intracellular reactive oxygen species level, suggesting oxidative stress. We 
also showed that it causes significant DNA damage, as assessed via the comet assay and 
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quantification of 8-oxo-dGuo using high performance liquid chromatography coupled to tandem 
mass spectrometry (HPLC-MS/MS), as well as elevation of DNA repair capacities in exposed cells 
[13,14]. The same conclusions were obtained on BEAS-2B cells, which is a normal bronchial cells [13]. 
3.1. Phosphoproteome Analysis 
Phosphoproteomes of control cells and cells exposed to TiO2-NPs were analyzed after 
enrichment by high-resolution tandem mass spectrometry [37]. As shown in Figure 1, 
phosphopeptides in both non-exposed and exposed cells were enriched for each of the three 
biological replicates, resulting in two separate fractions (#1 and #2) per sample. These two samples 
were analyzed separately over a 90-min gradient by nanoLC-MS/MS with a high-resolution mass 
spectrometer, and the results were merged (Supplementary Table S1). 
Among the recorded spectra for the three biological replicates 10,472 and 11,754 were assigned 
to human peptides in control cells and cells exposed to TiO2-NPs, respectively, corresponding 
respectively to 1310 and 1283 unique peptides (Supplementary Table S1). Among them, 88–90% were 
phosphorylated: they mainly carried one phosphorylation (66–70%), but sometimes two (18–24%) 
and more rarely three (0.2%). This corresponds to 1606 unique phosphorylation sites (P-sites), which 
are listed in Supplementary Table S2. These peptides belong to 644 and 649 proteins in control cells 
and cells exposed to TiO2-NPs, respectively, 96% and 93% of them being phosphorylated, i.e., 606 
phosphoproteins in control cells and 617 phosphoproteins in cells exposed to TiO2-NPs that are 
reported in Table S3. Among these proteins, 510 were detected in both control cells and cells exposed 
to TiO2-NPs (Supplementary Table S3, Figure 1). 
3.2. Comparison of Phosphorylation Levels in Control Cells and Cells Exposed to TiO2-NPs 
We compared the protein phosphorylation level in control cells and in cells exposed to TiO2-NPs 
using three criteria. First, we compared the phosphorylation counts, i.e., the numbers of 
phosphorylated residues detected on all the peptide sequences taking into account the Peptide-to-
Spectrum Matches. The second criterion was the phosphopeptide count, i.e., the number of spectra 
of phosphopeptides detected in the samples. The third criterion was the phosphorylated sites count, 
i.e., the number of unique phosphorylated sites on the detected peptides (see Figure S1 for a 
schematic representation). Using these three criteria, when analyzing the list of phosphopeptides 
detected in the samples, normalized with respect to individual protein molecular weights, the overall 
phosphorylation level did not statistically differ in CTL cells, compared to cells exposed to TiO2-NPs 
(Figure S2). When using these three criteria to analyze the phosphorylation level of each individual 
phosphoprotein, we identified significant differences between control cells and cells exposed to TiO2-
NPs. The fact that these two complementary analyses led to opposite phosphorylation trends 
suggests that many phosphorylatable sites (P-sites) showed different phosphorylation level rather 
than a strong modification of phosphorylation level of a few P-sites (here, phosphorylatable sites are 
considered as those that have been identified phosphorylated at least once in a biological sample in 
the experiment). As reported in Figure 2, out of the 510 phosphoproteins identified in both control 
and TiO2-exposed cells, 89 proteins (17.5%) showed different phosphorylation levels in cells exposed 
to TiO2-NPs as compared to control cells according to at least one of the three criteria (Category 1). 
Twenty-six proteins showed different phosphorylation levels according to all three criteria (Category 
2). Most of these phosphoproteins showed increased phosphorylation levels in cells exposed to TiO2-
NPs, compared to control cells (Figure 2). 
When using the same approach on individual P-sites, out of the 1606 detected P-sites, 139 
showed different phosphorylation levels in control and TiO2-exposed cells. These 139 P-sites 
belonged to 111 phosphoproteins (Category 3). Contrary to what was found when analyzing protein 
phosphorylation level, 70% of P-sites were less phosphorylated in TiO2-NP-exposed cells than in 
control cells. Therefore, the overall protein phosphorylation level is not affected in cells exposed to 
TiO2-NPs. Considering the strong affinity of TiO2 towards phosphate groups, and the intense 
accumulation of these TiO2-NPs in A549 cells (see [31], where these TiO2-NPs are referred to as TiO2-
Degussa), a much more intense dysregulation of the overall protein phosphorylation levels was 
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expected. Our results suggest that the impact of TiO2-NPs on the cellular phosphoproteome is much 
more finely tuned. This could be explained by the cellular distribution of TiO2-NPs in A549 cells, 
which shows preferential location in endosomes and/or lysosomes [31]. Sequestration in such 
compartments would limit the contact of TiO2 with phosphoproteins. 
 
Figure 2. Comparison of different phosphorylation levels. (a) Distribution of the number of proteins 
included in the different study groups. Whole-protein analysis groups (Cat. 1 and 2) and 
phosphorylation sites (Cat. 3); (b) Distribution of up- (red) or down-regulated (blue) (fold-change ≥ 
1.5, p-value < 0.05) phosphorylation levels in terms of whole protein indicators (phosphorylation, 
phosphopeptide and phosphorylated site counts) or phosphorylation level. 
3.3. Functional Analysis 
3.3.1. Protein Ontology 
The list of phosphocounts, phosphopeptides and phosphosites showing modulated 
phosphorylation level (p < 0.05) was analyzed via protein ontology, using David and Ingenuity® 
Pathway Analysis (IPA, Qiagen, Courtaboeuf, France), followed by data mining using the Uniprot 
protein annotation. The whole human proteome was used as reference group. Since both David and 
IPA analyses, based on the lists of individual P-sites, phosphocounts or phosphopeptides, 
highlighted the same cellular functions and processes, we present here the results obtained using 
David and the analysis performed on the list of phosphopeptides, showing a false discovery rate 
(FDR) lower than 20% (Table 1). All GO terms identified on the list of phosphopeptides are reported 
in Table S4. 
The list of GO terms obtained when analyzing phosphocounts (cluster analysis) and P-sites are 
reported in Supplementary Tables S5 and S6, respectively. The GO terms obtained via IPA, in the 
pathways “Diseases and Biofunctions”, for proteins listed in category 1, 2, and 3 are reported in 
Supplementary Tables S7–S9, respectively. For most of these proteins, the link between the 
phosphorylation status and their function is not established. Therefore, here, we report the overall 
function of these phosphoproteins, and if available, the role played by phosphorylation in their 
function. 
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Table 1. List of GO terms deduced from analysis of the list of phosphopeptides, with cutoff FDR 1 at 20%. 
Category Term Count % p-Val. List Tot. Fold Enrich. FDR 
UP_KEYWORDS Phosphoprotein 81 96.429 0.000 84 2.41 0.00 
UP_KEYWORDS Acetylation 40 47.619 0.000 84 2.86 0.00 
UP_KEYWORDS Cytoplasm 43 51.190 0.000 84 2.19 0.00 
GOTERM_CC_DIRECT cell-cell adherens junction 12 14.286 0.000 82 8.26 0.00 
GOTERM_CC_DIRECT nucleoplasm 32 38.095 0.000 82 2.55 0.00 
UP_KEYWORDS Methylation 18 21.429 0.000 84 4.41 0.00 
GOTERM_BP_DIRECT cell-cell adhesion 11 13.095 0.000 79 8.63 0.00 
UP_KEYWORDS Ubl conjugation 23 27.381 0.000 84 3.31 0.00 
GOTERM_MF_DIRECT protein binding 65 77.381 0.000 83 1.50 0.00 
GOTERM_CC_DIRECT focal adhesion 12 14.286 0.000 82 6.82 0.00 
GOTERM_MF_DIRECT cadherin binding involved in cell-cell adhesion 11 13.095 0.000 83 7.71 0.00 
GOTERM_CC_DIRECT cytosol 34 40.476 0.000 82 2.28 0.00 
UP_KEYWORDS Isopeptide bond 18 21.429 0.000 84 3.90 0.00 
GOTERM_CC_DIRECT cytoplasm 42 50.000 0.000 82 1.79 0.03 
GOTERM_MF_DIRECT poly(A) RNA binding 18 21.429 0.000 83 3.24 0.03 
UP_KEYWORDS Cytoskeleton 16 19.048 0.000 84 3.44 0.05 
UP_KEYWORDS Nucleus 39 46.429 0.000 84 1.82 0.06 
UP_KEYWORDS Alternative splicing 60 71.429 0.000 84 1.39 0.25 
GOTERM_CC_DIRECT actin cytoskeleton 7 8.333 0.000 82 7.14 0.52 
GOTERM_CC_DIRECT nucleus 39 46.429 0.001 82 1.60 0.98 
UP_KEYWORDS Host-virus interaction 8 9.524 0.001 84 5.09 1.13 
GOTERM_CC_DIRECT membrane 21 25.000 0.001 82 2.12 1.55 
UP_SEQ_FEATURE mutagenesis site 20 23.810 0.001 83 2.21 1.57 
UP_KEYWORDS Cell junction 10 11.905 0.002 84 3.63 1.90 
GOTERM_BP_DIRECT osteoblast differentiation 5 5.952 0.001 79 10.22 2.03 
GOTERM_CC_DIRECT Z disc 5 5.952 0.002 82 9.42 2.33 
GOTERM_MF_DIRECT actin binding 7 8.333 0.002 83 5.12 2.89 
UP_SEQ_FEATURE Nuclear localization signal 7 8.333 0.003 83 4.92 3.96 
UP_KEYWORDS Coiled coil 23 27.381 0.004 84 1.86 4.43 
GOTERM_CC_DIRECT cell projection 4 4.762 0.005 82 11.85 5.50 
GOTERM_BP_DIRECT microtubule cytoskeleton organization 4 4.762 0.004 79 11.98 6.27 
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UP_KEYWORDS Apoptosis 8 9.524 0.006 84 3.66 6.95 
GOTERM_BP_DIRECT regulation of cellular response to heat 4 4.762 0.005 79 11.34 7.28 
GOTERM_MF_DIRECT 14-3-3 protein binding 3 3.571 0.006 83 25.42 7.31 
GOTERM_CC_DIRECT perinuclear region of cytoplasm 9 10.714 0.006 82 3.22 7.55 
GOTERM_BP_DIRECT insulin receptor signaling pathway 4 4.762 0.006 79 10.90 8.09 
GOTERM_CC_DIRECT intracellular membrane-bounded organelle 8 9.524 0.012 82 3.19 13.93 
INTERPRO Microtubule associated protein 1 2 2.381 0.013 80 154.66 15.24 
GOTERM_BP_DIRECT viral process 6 7.143 0.013 79 4.27 17.15 
GOTERM_BP_DIRECT negative regulation of extrinsic apoptotic signaling pathway 3 3.571 0.013 79 16.78 18.06 
UP_KEYWORDS RNA-binding 8 9.524 0.018 84 2.95 19.65 
GOTERM_BP_DIRECT erythrocyte differentiation 3 3.571 0.015 79 15.94 19.73 
KEGG_PATHWAY Focal adhesion 5 5.952 0.020 36 4.64 19.96 
UP_KEYWORDS Fatty acid biosynthesis 3 3.571 0.019 84 14.14 20.54 
GOTERM_CC_DIRECT cytoplasmic vesicle membrane 4 4.762 0.019 82 7.06 20.83 
GOTERM_MF_DIRECT 1-phosphatidylinositol-3-kinase activity 3 3.571 0.019 83 14.19 20.99 
1 FDR: false discovery rate (in %) only FDR < 50% are reported. “List tot.”: number of input proteins retained for testing the GO term. “Count”: number of genes 
annotated with tested GO term. %: ratio between the two. p-Val. (p-value): statistical risk associated with tested GO term. FDR: false discovery rate taking into 
account multiple testing of GO terms. Fold Enrich (Fold Enrichment): composite probability score of the relevance of GO term.
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Among the GO terms identified by David, “apoptosis” (FDR 6.95%) and “negative regulation of 
extrinsic apoptotic signaling pathway” (FDR 18%) attracted our attention, since apoptosis has already 
been described as being one of the cellular processes induced by TiO2-NPs [1]. The proteins identified 
here and involved in these pathways are EPHA2, BAG6, ACIN1, HTT, BAG3, MAP1S, SQSTM1, 
TPX2, CTTN, SON, KRT18, ADAR, and LYRIC. EPHA2 participates in UV-induced apoptosis [45] 
and ACIN1 induces chromatin condensation [46]. BAG3 exhibits anti-apoptotic activity when bound 
to BCL-2 [47]. TPX2 participates in the assembly of microtubules during apoptosis [48]. Some of these 
proteins also play roles in the autophagic process, which is also known as being dysregulated in cells 
exposed to TiO2-NPs [22,49,50]. For instance, MAP1S activates autophagy and consequently reduces 
cell propensity to undergo apoptosis [51]. HTT is implicated in autophagic vesicles formation [52] 
and it is phosphorylated in response to DNA damage; its phosphorylation is linked with its toxicity 
[53]. SQSTM1, when linked to p62, constitutes a selective autophagy receptor that directs 
ubiquitinated substrates to degradation [54], while SPP1 regulates ER stress-induced autophagy [55] 
and RB1 is also involved in autophagy [51]. In line with this observation, we previously showed that 
repeated exposure of A549 cells for 2 months to the same TiO2-NPs as in the present study leads to 
significant accumulation of TiO2-NPs in autophagic vesicles and increased LC3II/LC3I ratio, 
suggesting alteration of the autophagic process [49]. This alteration would result from modulation of 
the phosphorylation of these proteins. Moreover, some of these proteins play roles in the DNA 
damage response, which is activated in TiO2-NP-exposed cells, particularly via impairment of the 
DNA repair as previously demonstrated in A549 cells exposed to the same TiO2-NPs and in the same 
conditions as in the present study [13,14] and via modulation of cell cycle progression [15-20]. This is 
the case of BAG6, which is involved in DNA-damage induced apoptosis by binding EP300, itself 
involved in the regulation of TP53 transcriptional activity [56]. Moreover, phosphorylated ACIN1 
modulates the expression of cyclin A1 that is involved in the control of cell cycle progression, 
particularly in the transitions between G1 and S phase and between G2 and M phase [57]. SON is 
involved in splicing of many DNA-repair transcripts, and is required for the progression of the cell 
cycle [58]. In addition, ITGAV is involved in TGF-β1 activation [59], while RB1 regulates the entry 
into cell division. It is either active or inactive depending on its phosphorylation status. Depending 
on its phosphorylation level, it is also involved in TGF-β1-induced apoptosis [60]. Moreover, NDRG1 
shows different phosphorylation level in cells with active cell cycle or with blocked cell cycle [61,62]. 
Its phosphorylation level controls its nuclear localization and its role in cell division, DNA repair and 
proteasomal degradation [62]. Analysis of the cell cycle in A549 cells exposed to 100 µg/mL of TiO2-
NPs for 24 h shows a mild but statistically significant reduction of the proportion of cells in the G1 
phase, as compared to unexposed cells (Supplementary Figure S3). Moreover, after repeated 
exposure of A549 cells to the same TiO2-NPs as in the present study, we previously observed 
decreased cell proliferation and perturbation of the cell cycle [49,63]. Moreover, a significant increase 
of the proportion of cells in the sub-G1 phase is observed, implying that some cells undergo apoptosis 
(Supplementary Figure S3). This suggests that this effect on the cell cycle, visible at the scale of the 
phosphoproteome, translates into a phenotypic effect, which is revealed after acute and prolonged 
exposure. 
Our analysis highlights the central role of TP53 in these processes, as illustrated by a network 
identified using IPA (Figure 3). This network focuses on cellular assembly and organization, DNA 
replication, recombination and repair, and cancer pathways. The phosphorylation of TP53 itself is 
not shown to be affected, but p53 acts as an upstream transcriptional regulator of several proteins 
having modulated phosphorylation levels (SKIV2L, TPX2, BAG6, SON, KIF4A, POP1, RPLP1, 
DERL1, MARK2, ZC3HC1, PHC3). We previously showed that repeated exposure of A549 cells to 
the same TiO2-NPs as in the present study, up to two months, leads to increased phosphorylation 
and acetylation of TP53 [49]. This suggests that the TP53 pathway is activated in A549 cells exposed 
to these TiO2-NPs. Induction of DNA damage and/or apoptosis is known to be related to activation 
of the TP53 pathway [64–69], we show here that these cellular processes are at least partly impacted 
via dysregulated phosphorylation. 
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Impaired cell cycle progression induced by TiO2-NPs is generally reported as cell accumulation 
in S or G2-M phases [15–20]. It is concomitant with impairment of mitotic progression, formation of 
multipolar mitotic spindles, abnormal chromosome segregation during anaphase and telophase, with 
deregulation of the function of PLK1 kinase [12]. The present analysis suggests that dysregulated 
phosphorylation may be a mechanism through which all these processes are affected. 
 
Figure 3. IPA® protein network illustrating the central role of p53 in TiO2-NP impact. This IPA® 
protein network illustrates molecular orchestration of cellular development, movement, and 
morphology. Proteins depicted in red have been detected in our dataset, while non-colored proteins 
were not detected. Two genes products showing binding are represented by a line, and an arrow is 
indicated when a gene product acts on another one. The blue lines highlight the connections to TP53. 
Several pathways identified by David-based analysis are related to disturbance of the 
cytoskeleton, both actin cytoskeleton and microtubules (“Cytoskeleton” FDR 0.05%, “actin 
cytoskeleton” FDR 0.52%, “actin binding” FDR 2.89%, “microtubule cytoskeleton organization” FDR 
6.27%, etc.). Some of these proteins play roles in cell migration, motility, and adhesion. For instance, 
TLN2 is a component of focal adhesion plates and is involved in cell adhesion in synapses, ZYX is a 
stabilizer of focal adhesions in muscle cells and synapses [70], and CTTN is involved in cell migration 
and the formation of metastases [71]. Other proteins rather play roles in cellular structure, such as 
MAP1B, which is involved in microtubule polymerization and stabilization, in the formation of 
autophagosomes and in membrane blebbing [72]. Likewise, MPRIP stabilizes actin fibers and plays 
a role in development of stress fibers [73] and KIF4A is necessary for successful cytokinesis [74]. 
Moreover, some of these proteins are involved in intracellular trafficking, such as NDRG1, which is 
involved in trafficking of vesicles and lipids and CTTN, which is involved in protein trafficking and 
in endocytosis [75]. This impact on the cytoskeleton is illustrated by a second network identified 
using IPA, which involves 35 proteins and illustrates the impact of TiO2-NPs on cellular development, 
movement and morphology (Figure 4). 
Transmission electron microscopic observation of these cells exposed to TiO2-NPs showed 
strong accumulation of NPs inside cells, and localization in cytoplasmic vesicles (Figure 5). This 
accumulation did not lead to any change in the morphology of cells, and we did not detect the 
presence of stress fibers (Figure 5). 
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Figure 4. IPA® protein network illustrating the links between proteins involved in TiO2-NP impact on 
the cytoskeleton. Proteins depicted in red have been detected in our analysis, while non-colored 
proteins were not identified. Two genes products showing binding are represented by a line, and an 
arrow is indicated when a gene product acts on another one. 
 
Figure 5. Transmission electron microscopic observation of A549 cells exposed to TiO2-NPs. (a) 
Control cells; (b,c) cells exposed to 100 µg/mL TiO2-NPs for 24 h. 
The impact of TiO2-NPs on cytoskeleton integrity highlighted in this phosphoproteome analysis 
is consistent with the literature [17,76–84]. Indeed, TiO2-NPs have been shown to impair the 
expression of genes involved in cytoskeleton maintenance [17,81]. It has also been shown to induce 
disorganization of microtubules and of the actin network [76,79,80,83]. Moreover, in an acellular 
study, TiO2-NPs were also shown to inhibit tubulin polymerization and change its conformation [77]. 
Again, we show here that dysregulated phosphorylation of some phosphoproteins may be a 
mechanism leading to this impact. 
In addition, several pathways identified in this gene ontology search are related to RNAs and 
their processing (“poly(A) RNA binding” FDR 0.03, “alternative splicing” FDR 0.25, “RNA-binding” 
FDR 19.65), particularly to splicing of pre-mRNA and mRNA (SON, SNRNP200, SRRM1, ADAR, 
ACIN1). SON is a cofactor for transcript splicing, especially for transcripts related to cell cycle and 
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DNA repair [85], while SNRNP200 is involved in spliceosome assembly and activation and it is a 
putative helicase [86]. SRRM1 is part of the mRNP granules, which regulate mRNA translation, 
localization, and recycling [87]. ADAR is involved in the editing of double-stranded RNA [88], which 
affects mRNA translation. ACIN1 is part of the exon junction complex, which is involved in mRNA 
processing [89]. One of these proteins is a component of the MRP ribonuclease complex and of 
ribonuclease P, which is involved in the generation of mature tRNA and (POP1). Finally, one of these 
proteins is a helicase involved in the biogenesis of 60 S ribosomal subunits (DDX51). This suggests a 
possible impact of TiO2-NPs on translation, which would be mediated by dysregulated 
phosphorylation of some phosphoproteins. RNA-binding proteins have been reported to bind to SiO2 
nanoparticles, and consequently to affect translation [90]. The present results suggest that TiO2-NPs 
could also affect translation through modulation of the phosphorylation of proteins involved in RNA 
processing. This would explain the overall gene expression downregulation that we previously 
observed in A549 cells exposed to the same TiO2-NPs, and in the same exposure conditions [13]. 
Finally, several proteins are involved in molecular transport (ADAR, CTTN, HTT, NUP214 and 
SEC61B), in and out of the nucleus in particular. NUP214 is a nucleoporin involved in nuclear export 
[91] and SEC61B is responsible for the nuclear import of proteins, in particular the epidermal-growth 
factor receptor (EGFR) [92]. Moreover, SQSTM1 also shows dysregulated phosphorylation level. It 
has been reported that chromosomal translocation leads to the production of a NUP214-SQSTM1 
fusion protein that forms nuclear bodies, which shuttle between the nuclear and cytoplasmic 
compartments, and may be a form of storage of nuclear transport proteins [93]. Dysregulated 
phosphorylation levels of NUP214 and SQSTM1 might be the result of dysregulated levels of the 
single proteins, or of the fusion protein. Modulation of the phosphorylation profile of these proteins 
might affect the nuclear localization of some key proteins, for instance, some proteins involved in 
DNA repair, explaining the accumulation of DNA caused by TiO2-NPs [11] or impaired DNA repair 
activities [13,14]. These results are consistent with recent studies, which report that TiO2-NPs 
dysregulate the expression of genes or proteins related to ion transport [81,84], trans-membrane 
transport [94,95], and molecular transport inside the cell [29,96].  
3.3.2. Biological Activity of Dysregulated Phosphorylation Sites 
We then analyzed the literature relative to the function of the 139 dysregulated P-sites, which 
would explain some of the impacted biological activities. The biological function of only 14 P-sites is 
known (Table 2). Some kinases responsible for the phosphorylation of these P-sites have been 
reported, while phosphatases are known only for two of them, namely CTTN421 and CARHSP141, 
which are dephosphorylated by PTP1B and PP2A, respectively [78,97]. Again, the two main functions 
that are impacted via these dysregulated P-sites are cell cycle regulation and cytoskeleton 
organization. AKAP1151, ENSA67, ERF526, FLNA1084, KIF4A801, MISP397 and RB1826 have been shown to 
regulate the cell cycle [98–104], while AKAP1151, CTTN421, FLNA1084, HSPB115 and VIM56 have been 
reported to be involved in cytoskeleton organization [97,98,103,105–109]. 
Other functions are identified through this approach, i.e., the oxidative stress response (HSPB115 
and CARHSP141) [105,108,110–112] and inflammatory processes (VIM56 and NDRG1330) [107,113]. Both 
oxidative stress and inflammation are hallmarks of TiO2-induced cellular stress [1]. We show here 
that dysregulated phosphorylation of some key proteins may at least partly drive these effects. 
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Table 2. Dysregulated phosphorylation sites with a known biological function. 
P-site FC Protein Activities Site-Specific Phosphorylation Role Kinase Reference 
KIF4A801 3 Kinesin motor, plays a role in mitosis 
Inhibition of PRC1-microtubule overlaps at the central 
spindle during mitosis 
AURORA-B [101] 
ERF526 2.25 
Repressor of the transcription. Tumor 
suppressor. Sensor of ERK activity, 
affects cell cycle progression. 
Regulates nuclear export of ERF. Promotes cell cycle 
arrest in G1 phase. Decreases ERF repression of the 
transcription 
ERK [99] 
MISP397 2 
Plays a role in mitosis: mitotic spindle 
orientation and mitosis progression. 
Regulates mitotic spindle positioning, which is required 
for the definition of the correct cell division axis 
PLK1 [104] 
NDRG1330 1.7 
Plays roles in apoptosis, cell growth 
and differentiation, mitosis, cell 
trafficking, hormone response. Tumor 
metastasis suppressor.  
Cell cycle-dependent phosphorylation (temporally and 
spatially). Regulates the expression of CXC chemokine 
and acts on NFκB signaling pathway.  
SGK1 [113] 
VIM56 1.6 
Transport of intracellular vesicles 
(lysosomes, secretion granules) 
During acute inflammation, plays a role in granule 
secretion in neutrophils. 
CDK5 [107] 
FLNA1084 1.6 
Links actin filaments to cell membrane 
glycoproteins, and various proteins to 
the actin cytoskeleton. Role in cell-cell 
contact and signal transduction 
Involved in the separation of daughter cells after mitosis, 
as well as cell migration. 
CDK1 [103] 
ENSA67 1.5 Inhibitor of PP2A phosphatase 
Regulates the activity of PP2A phosphatase, which 
regulates cyclin-B1-CDK1 activity high during M phase 
CDK1-activated 
GWL [100] 
RB1826 1.5 
Tumor suppressor. Regulator of cell 
division. Maintenance of 
heterochromatin structure 
Regulate the binding of RB1 with E2F transcription 
factors, necessary for G1-S transition during cell cycle 
progression  
CDK2-CyclinE/A [102] 
CARHSP141 −1.6 Regulates the stability of mRNAs Promotes/inhibits single-strand DNA binding. Localizes 
CRHSP1 at stress granules in condition of oxidative stress 
DYRK isoform, 
among other 
kinase(s) of proline  
[110–112] 
PIK3C2A259 –2 
Role in intracellular trafficking, 
particularly for insulin signaling, 
endocytosis process. Role in EGF 
signalling cascade, mitosis, response to 
UV-induced damage. 
Phosphorylation regulates PIK3C2A conformation, its 
cellular localization and its degradation 
CDC2 or UV 
irradiation+ 
JNK/SAPK 
[114–116] 
AKAP1151 −2 
Regulates the localization of 
regulatory subunits of protein kinase 
A, either on mitochondrial membranes 
or in the endoplasmic reticulum. 
AKA1 is associated with PP1 in G1 phase of the cell cycle; 
phosphorylation of S151 in AKAP1 leads to dissociation 
of this interaction at the G1/S transition.  
PKC [98] 
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PTGES3113 −2.1 
Prostaglandin PGE2 synthase, 
promotes disassembly of transcription 
regulation complexes by binding on 
genomic response elements. 
Phosphorylation activates this enzyme, by promoting the 
formation of a cPGES-CK-II-Hsp90 complex.  
CK-II [117] 
HSPB115 −2.3 
Molecular chaperone. Protects unfolded 
proteins during oxidative stress. Role in 
actin filament dynamics, important for 
cell motility 
Phosphorylated in response to cellular stress. Causes 
dissociation of Hsp complexes, which decreases their 
chaperone activity 
MAPKAP2 [105,108] 
CTTN421 −2.3 
Involved in the organization of actin 
cytoskeleton. Role in cell migration, in 
the formation of metastases, in the 
formation of protein complexes at 
focal adhesions, in endocytosis and 
intracellular transport 
Phosphorylation by SRC promotes cell motility, where 
phosphorylated CTTN acts as a linker between F-actin 
and focal adhesions. Promotes the endothelial cell barrier 
function enhancement triggered by S1P.  
SRC in response to 
EGFR activation [97,106,109] 
FC: phosphorylation level fold-change, exposed cells vs. control cells. 
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4. Conclusions 
Analysis of the phosphoproteome of A549 cells exposed to TiO2-NPs reveals that these 
nanoparticles affect DNA damage response, by means of dysregulation of the cell cycle and DNA 
repair, the process of autophagy, the cytoskeleton dynamics and structure, the RNA dynamics, as 
well as intracellular transport. It highlights the central role of p53 in some of these processes. 
Although these effects of TiO2-NPs have already been reported using other techniques, here we 
suggest that there is a link between the dysregulation of phophoprotein phosphorylation status and 
these cellular events, using an exposure condition that does not induce any overt cytotoxicity. It 
should be highlighted that the A549 cell line is derived from an alveolar carcinoma. Therefore, it 
would be important to repeat this experiment on a non-cancerous cell line. This would demonstrate 
that the observed effects are not specific to cancer cells and that they are representative of the impact 
caused by inhalation exposure of healthy individuals to TiO2-NP. 
Supplementary Materials: The following are available online at https://www.mdpi.com/2079-4991/10/1/185/s1. 
Figure S1: Illustration of the three whole protein phosphorylation level indicators. Figure S2: Overall 
phosphorylation levels. Figure S3: analysis of the cell cycle. Table S1: List of MS/MS spectra assigned to human 
peptides in control cell datasets (Ctrl) and TiO2-NP-exposed cell datasets (TiO2). Table S2: List of unique 
phosphorylation sites detected in control cell datasets (Ctrl) and TiO2-NP-exposed cell datasets (TiO2). Table S3: 
List of detected phosphoproteins, provided together with phosphorylation counts. Table S4: List of GO terms 
identified using David with phosphopeptides. Table S5: List of GO terms identified using David with 
phosphocounts (clustered). Table S6: List of GO terms identified using David with P-sites. Tables S7–S9: List of 
GO terms (IPA) revealed from phosphoproteins from Cat. 1, Cat. 2 and Cat. 3, respectively. 
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